interventional study protocol, the authors describe the study rationale, study design, study population and study objectives and outcome measures of the A-SURE study which started in December 2016. The rFVIIIFC pivotal studies demonstrated that it was safe and efficacious in the treatment and prevention of bleeds in pediatric and adults patients. rFVIIIIFC is currently approved and used in many countries. Recent long-term clinical trial data indicate that it remains consistent in its efficacy and safety profile in the clinical trial setting. There is a paucity of real-life data on the effectiveness of rFVIIIFC when compared to other FVIII products used in real life setting. While a head-to-head comparison of rFVIIIFC with the standard of care FVIIII product would be the ideal to demonstrate effectiveness , the number, and types of FVIII products currently on the market would make this study difficult to execute and interpret. Therefore, the authors have chosen a more practical study design comprising of a pre-study 12-month retrospective data collection and on-study 24-month data collection of the effectiveness of rFVIIIFC when used in real life setting for bleed prevention. Given the size of the study participating centers, the target study population number should be achievable. The choice of primary and secondary study objectives are appropriate. In line with current outcome measures, I would have liked to see the zero bleed rates as one of the study objectives. And also, the exclusion of the collection of safety data has missed the opportunity to demonstrate the real-life safety of rFVIIIFC outside clinical studies. The data collection methodology and tools are standard and appropriate. It is not clear from the protocol description if data collection will be done on paper or using electronic tools. There is growing evidence that electronic data collection reduces the error rates and increase compliance as many electronic data collection tools have reminders. Statistical analysis is standard for this design. Whilst it is not included in the analysis, it would be informative to see an intra-individual comparison across a number of endpoints in the 12 months prior and 24 months on study. 
REVIEWER

GENERAL COMMENTS
In your secondary endpoints you talk about Treatment Adherence Scale-Prophylaxis. I think that this is Veritas-PRO assessment instrument, if it is, it would be useful to state this for clarity.
One thing I'm not sure about is how 'bleeds' will be diagnosed -will you take data from patient diaries of self-reported bleeding (you say 'local practice') OR will the bleeds somehow be more defined through hospital attendance and review?
There is slight confusion over recruitment -you have possibly 50 centres, are hoping to recruit 150-175 participants (3-4/centre if all 50 sign up to study) yet also state that centres will be asked to recruit 'all eligible patients' this might/will give many more potential trial subjects; how will you stop over-recruitment?
Other than that, this is a very nice study and I look forward to seeing the results.
REVIEWER
SILVA ZUPANČIĆ ŠALEK National HAemophilia and thrombophiia CTR, Dept of Haematology, University Hospital Centre Zagreb, Rebro, Zagreb, Croatia REVIEW RETURNED 22-Jan-2019
GENERAL COMMENTS
The study design is clearly defined as well as the outcomes of the study. This will be the first study to provide prospective data on the succsesfulness of porphy with rFVIIIFc and conventional FVIII concentrates in PWH A in routine practice. It should minimized the bias in the A-SURE study.
VERSION 1 -AUTHOR RESPONSE
Reviewer(s) Reports:
Reviewer: 1 Please leave your comments for the authors below In this paper, "Design of a prospective noninterventional study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study", Oldenburg and colleagues describe a study protocol for ongoing research study looking at the efficacy of Factor VIIIFc compared to standard factor VIII products for prophylaxis. This study is straightforward with clear objectives and the paper written well.
I have no major comments.
minor comments:
From anyone 1) Please delete "and to arrest any breakthrough bleeds" on page 3 lines 73-74. Answer: Text has been deleted in the updated version of the manuscript.
2) Please correct grammar on page 4, line 94 Answer: We have changed the sentence from:
"Results from ASPIRE have demonstrated sustained safety and efficacy of rFVIIIFc over an up to a 4-years long follow-up period, with low annualised bleeding rates (ABR)." to:
"Results from ASPIRE have demonstrated sustained safety and efficacy of rFVIIIFc, with low annualised bleeding rates (ABR), over a period of up to 4 years."
Reviewer: 2
Reviewer Name: Johnny Mahlangu Institution and Country: University of the Witwatersrand South Africa Please state any competing interests or state 'None declared': None Please leave your comments for the authors below Design of a prospective non-interventional study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study.
A-SURE is a multicentre study conducted in five European countries to evaluate the effectiveness of rFVIIIFC in a real-life setting when used for bleed prevention. In this ongoing non-interventional study protocol, the authors describe the study rationale, study design, study population and study objectives and outcome measures of the A-SURE study which started in December 2016.
The rFVIIIFC pivotal studies demonstrated that it was safe and efficacious in the treatment and prevention of bleeds in pediatric and adults patients. rFVIIIIFC is currently approved and used in many countries. Recent long-term clinical trial data indicate that it remains consistent in its efficacy and safety profile in the clinical trial setting. There is a paucity of real-life data on the effectiveness of rFVIIIFC when compared to other FVIII products used in real life setting.
While a head-to-head comparison of rFVIIIFC with the standard of care FVIIII product would be the ideal to demonstrate effectiveness , the number, and types of FVIII products currently on the market would make this study difficult to execute and interpret. Therefore, the authors have chosen a more practical study design comprising of a pre-study 12-month retrospective data collection and on-study 24-month data collection of the effectiveness of rFVIIIFC when used in real life setting for bleed prevention. Given the size of the study participating centers, the target study population number should be achievable. The choice of primary and secondary study objectives are appropriate. In line with current outcome measures, I would have liked to see the zero bleed rates as one of the study objectives.
Answer: We thank Dr Mahlangu for the thorough review. There is a minor mistake in Dr Mahlangu's summary. The study will be conducted in 50 haemophilia centres across Europe, and not only in 5 countries as stated above. ABRs is one of the endpoints and therefore the study will be able to evaluate the proportion of zero bleeds, although this is not described as an objective.
And also, the exclusion of the collection of safety data has missed the opportunity to demonstrate the real-life safety of rFVIIIFC outside clinical studies.
Answer: To clarify how the study handles safety we have included a separate paragraph on safety on page 12 of the updated manuscript: "Safety This study is not designed to answer any safety questions. Therefore, only serious adverse events during rFVIIIFc treatment from 1st dose to 14 days following end of rFVIIIFc treatment or 14 days after the patients last study visit, whichever comes first, and non-serious adverse events leading to permanent discontinuation of rFVIIIFc will be captured. The adverse events will be reported to authorities in accordance with guideline on good pharmacovigilance practices, Module VI.
[16]"
The data collection methodology and tools are standard and appropriate. It is not clear from the protocol description if data collection will be done on paper or using electronic tools.
There is growing evidence that electronic data collection reduces the error rates and increase compliance as many electronic data collection tools have reminders.
Answer: An Electronic Case Report Form is used to collect study data, this has been clarified in the updated version of the manuscript. Patients are however given paper questionnaires to report 'Patient Reported Outcomes' (Secondary Objective). The manuscript has been updated with this information on page 9.
Statistical analysis is standard for this design. Whilst it is not included in the analysis, it would be informative to see an intra-individual comparison across a number of endpoints in the 12 months prior and 24 months on study.
